Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | GPR3 | P46089 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | USP5 | P45974 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5528658 | 0.78 | KDM4E (0.42) | KDM4EGPR3HPGDHSD17B10USP5 | |
| SCHEMBL4703998 | 0.78 | KDM4E (0.42) | KDM4EGPR3ERN1HPGDHSD17B10 | |
| SCHEMBL5823463 | 0.78 | KDM4E (0.42) | KDM4EGPR3ERN1HPGDHSD17B10 | |
| SCHEMBL10752885 | 0.78 | MAPT (0.54) | KDM4EERN1SMN1; SMN2RAB9ATSHR | |
| SCHEMBL5092806 | 0.78 | KDM4E (0.42) | KDM4EGPR3ERN1HPGDHSD17B10 | |
| SCHEMBL1486425 | 0.76 | KDM4E (0.41) | KDM4EGPR3ERN1HPGDHSD17B10 | |
| SCHEMBL27536516 | 0.76 | USP5 (0.39) | KDM4EGPR3ERN1HPGDHSD17B10 | |
| SCHEMBL2252071 | 0.75 | FGFR1 (0.54) | FGFR1RAB9AADORA3 | |
| SCHEMBL202924 | 0.75 | KDM4E (0.39) | KDM4EFGFR1SMN1; SMN2RAB9ATSHR | |
| SCHEMBL667481 | 0.75 | DPP4 (0.43) | SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3366311-B1 | HYDRAZINO-1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM | 3M INNOVATIVE PROPERTIES CO (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10406142-B2 | Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom | 3M LNNOVATIVE PROPERTIES COMPANY (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3366311-A1 | HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM | 3M Innovative Properties Co. (US) | 2018-08-29 | — | — | EP | disclosed |
| EP-2718292-B1 | HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM | 3M INNOVATIVE PROPERTIES CO (US) | 2018-03-14 | — | — | EP | disclosed |
| US-9856254-B2 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170173164-A1 | HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2017-06-22 | — | — | US | disclosed |
| US-9585968-B2 | Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160280707-A1 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2016-09-29 | — | — | US | disclosed |
| US-9365567-B2 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150352218-A1 | HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM | 3M INNOVATIVE PROPERTIES COMPANY | 2015-12-10 | — | — | US | disclosed |
| US-20030130518-A1 | Urea substituted imidazoquinoline ethers | COLEY PHARMACEUTICAL GROUP, INC. | 2003-07-10 | — | — | US | disclosed |
| US-20030100764-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-29 | — | — | US | disclosed |
| US-20030096835-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-22 | — | — | US | disclosed |
| US-20030065005-A1 | Heterocyclic ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-03 | — | — | US | disclosed |
| US-20020193396-A1 | Sulfonamido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-12-19 | — | — | US | disclosed |
| US-20020173655-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | disclosed |
| WO-2002046193-A2 | HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046191-A2 | UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046188-A2 | AMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046189-A2 | ARYL ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065005-A1 | Heterocyclic ether substituted imidazoquinolines | IFNG, IL2, IRF3 | KDM4E 752/4885GPR3 2207/4885ERN1 995/4885 |
| US-20170173164-A1 | HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM | IL15, IL2, HNMT | KDM4E 1721/4885GPR3 2917/4885ERN1 4874/4885 |
| US-20160280707-A1 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | KDM4E 1754/4885GPR3 2688/4885ERN1 2193/4885 |
| US-10406142-B2 | Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom | IL15, IL2, HNMT | KDM4E 1721/4885GPR3 2917/4885ERN1 4874/4885 |
| US-20150352218-A1 | HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM | IL15, IL2, HNMT | KDM4E 1721/4885GPR3 2917/4885ERN1 4874/4885 |
| US-20030130518-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | KDM4E 423/4885GPR3 3390/4885ERN1 215/4885 |
| US-20030096835-A1 | Amido ether substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | KDM4E 473/4885GPR3 2559/4885ERN1 273/4885 |
| US-20020173655-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | KDM4E 1675/4885GPR3 3124/4885ERN1 986/4885 |
| US-20030100764-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | KDM4E 1675/4885GPR3 3124/4885ERN1 986/4885 |
| US-20020193396-A1 | Sulfonamido ether substituted imidazoquinolines | IFNG, IRF3, IL2 | KDM4E 469/4885GPR3 3119/4885ERN1 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.